Drug Profile
A 285222
Latest Information Update: 24 Jan 2013
Price :
$50
*
At a glance
- Originator Abbott Laboratories
- Class
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma; Transplant rejection
Most Recent Events
- 31 Oct 2005 Discontinued - Preclinical for Asthma in USA (unspecified route)
- 31 Oct 2005 Discontinued - Preclinical for Transplant rejection in USA (unspecified route)
- 08 Oct 2004 No development reported - Preclinical for Transplant rejection in USA (unspecified route)